Luminopia develops a new class of treatments for significant neuro-visual disorders.
Luminopia has raised $16.0M in total funding. The most recent round was Series A. The last funding was announced in June 2023.
Luminopia's investors include U.S. Venture Partners, MassChallenge, Shangbay Capital, Sony Innovation Fund, Sesame Ventures.
Luminopia is headquartered in Cambridge, United States.
Luminopia develops a new class of treatments for significant neuro-visual disorders.
Luminopia is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Luminopia — Funding & Investors." VCBacked, June 27, 2023, https://www.vcbacked.co/company/luminopia. Accessed September 2, 2026.
VCBacked. (2023). Luminopia — Funding & Investors. Retrieved September 2, 2026, from https://www.vcbacked.co/company/luminopia
{{cite web |title=Luminopia — Funding & Investors |url=https://www.vcbacked.co/company/luminopia |website=VCBacked |access-date=September 2, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated